Surrogate Endpoints – Neither the End nor the Point
In an article published in June 2018 in JAMA Oncology, the FDA reviewed their accelerated approvals for malignant hematology and oncology drugs over the previous 25 years. In an earlier…
Read MoreStudy Design and Conduct
How to Successfully Prepare for Your Pediatric Study Plan
Although the implementation of laws surrounding the safety and efficacy of drugs and biologics started in the early 1900s, the inclusion of pediatric use in labeling has significantly lagged behind.…
Read More
Alzheimer’s Drug Development & Challenges to the Amyloid Hypothesis
In 2018, the FDA published a draft guidance on how to develop drugs to treat early Alzheimer’s Disease (AD). This document came in the wake of several high-profile late‑stage failures…
Read More
Federal and Regulatory Support for the Development of Novel Antibiotics
Antibiotics are among the most important medications in the modern healthcare toolbox and are essential safeguards against global pandemics. However, antibiotics can be challenging to develop, and more and more…
Read More
Intrinsic and Extrinsic Factors in Drug Development
Personalized medicine (also known as precision medicine) is one of today’s biggest drug development buzzwords. It certainly stirs the imagination – the notion that one day we may live in…
Read More
FDA Policies to Accelerate Development of Cell & Gene Therapies
FDA Commissioner Scott Gottlieb, M.D. and Director of the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D., released a joint statement on January 15, 2019 previewing new FDA…
Read More
Pharmacokinetic Considerations for Topically Applied Drugs
A topically applied drug is any medication that is applied to the body’s surface (e.g., skin, eyes) in order to achieve a desired local therapeutic effect. Many drug types fall under…
Read More